Ann Rheum Dis:一种新型可靠的银屑病关节炎指炎整体超声评分(DACTOS)

2020-05-21 xiangting MedSci原创

新型DACTOS评分是一种可用于解释指炎多种超声特征的可靠指标。

指炎是银屑病关节炎(PsA)最典型的特征之一,其终生患病率高,并被纳入PsA临床指标。肌肉骨骼超声(Msk-US)可以很容易地检测到指炎对手指解剖结构的侵袭并监测治疗效果。这项研究旨在确定PsA手部指炎的特征性病变,评估Msk-US对这些病变进行评分的可靠性,并建立一种指炎整体超声(DACTOS)评分。

在对PsA指炎使用Msk-US进行系统的文献综述后,12名风湿病专家参加了三轮Delphi程序和共识会议,以就表征指炎的超声基本病变和整体超声评分的组成达成共识。然后,进行了基于网络和基于患者的评估者内部和评估者间的可靠性练习,以评估那些纳入评分的病变。

DACTOS评分是通过将Delphi调查中选择的病变评分进行相加而获得的:皮下软组织水肿、屈肌腱鞘炎、腹膜外伸肌炎和滑膜炎。DACTOS评分的范围为0到25。在可靠性练习中,评分纳入超声病变的一致性为中等到优秀。

新型DACTOS评分是一种可用于解释指炎多种超声特征的可靠指标。DACTOS评分为手部指炎提供了有用的整体分析并有助于临床诊断,也可以作为伴指炎的PsA患者治疗和研究的有用工具。

原始出处:

Alen Zabotti. Novel and reliable DACTylitis glObal Sonographic (DACTOS) score in psoriatic arthritis. Ann Rheum Dis. May 2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2013368, encodeId=f5f5201336895, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jul 09 22:59:15 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784071, encodeId=b8bb1e840719b, content=<a href='/topic/show?id=85b0566000' target=_blank style='color:#2F92EE;'>#DACTOS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5660, encryptionId=85b0566000, topicName=DACTOS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c838337, createdName=zhlpower, createdTime=Sun Apr 11 15:59:15 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779007, encodeId=b9141e790074b, content=<a href='/topic/show?id=e94f19102d' target=_blank style='color:#2F92EE;'>#Actos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1910, encryptionId=e94f19102d, topicName=Actos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Fri Jun 19 19:59:15 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862790, encodeId=61bd1862e90a6, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Nov 17 20:59:15 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718754, encodeId=172e1e1875463, content=<a href='/topic/show?id=5a6456425fc' target=_blank style='color:#2F92EE;'>#指炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56425, encryptionId=5a6456425fc, topicName=指炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f67632615255, createdName=xiongliangxl, createdTime=Fri Mar 12 00:59:15 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1266184, encodeId=c1d0126618453, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sat May 23 03:59:15 CST 2020, time=2020-05-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2013368, encodeId=f5f5201336895, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jul 09 22:59:15 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784071, encodeId=b8bb1e840719b, content=<a href='/topic/show?id=85b0566000' target=_blank style='color:#2F92EE;'>#DACTOS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5660, encryptionId=85b0566000, topicName=DACTOS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c838337, createdName=zhlpower, createdTime=Sun Apr 11 15:59:15 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779007, encodeId=b9141e790074b, content=<a href='/topic/show?id=e94f19102d' target=_blank style='color:#2F92EE;'>#Actos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1910, encryptionId=e94f19102d, topicName=Actos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Fri Jun 19 19:59:15 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862790, encodeId=61bd1862e90a6, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Nov 17 20:59:15 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718754, encodeId=172e1e1875463, content=<a href='/topic/show?id=5a6456425fc' target=_blank style='color:#2F92EE;'>#指炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56425, encryptionId=5a6456425fc, topicName=指炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f67632615255, createdName=xiongliangxl, createdTime=Fri Mar 12 00:59:15 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1266184, encodeId=c1d0126618453, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sat May 23 03:59:15 CST 2020, time=2020-05-23, status=1, ipAttribution=)]
    2021-04-11 zhlpower
  3. [GetPortalCommentsPageByObjectIdResponse(id=2013368, encodeId=f5f5201336895, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jul 09 22:59:15 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784071, encodeId=b8bb1e840719b, content=<a href='/topic/show?id=85b0566000' target=_blank style='color:#2F92EE;'>#DACTOS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5660, encryptionId=85b0566000, topicName=DACTOS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c838337, createdName=zhlpower, createdTime=Sun Apr 11 15:59:15 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779007, encodeId=b9141e790074b, content=<a href='/topic/show?id=e94f19102d' target=_blank style='color:#2F92EE;'>#Actos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1910, encryptionId=e94f19102d, topicName=Actos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Fri Jun 19 19:59:15 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862790, encodeId=61bd1862e90a6, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Nov 17 20:59:15 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718754, encodeId=172e1e1875463, content=<a href='/topic/show?id=5a6456425fc' target=_blank style='color:#2F92EE;'>#指炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56425, encryptionId=5a6456425fc, topicName=指炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f67632615255, createdName=xiongliangxl, createdTime=Fri Mar 12 00:59:15 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1266184, encodeId=c1d0126618453, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sat May 23 03:59:15 CST 2020, time=2020-05-23, status=1, ipAttribution=)]
    2020-06-19 yyj062
  4. [GetPortalCommentsPageByObjectIdResponse(id=2013368, encodeId=f5f5201336895, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jul 09 22:59:15 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784071, encodeId=b8bb1e840719b, content=<a href='/topic/show?id=85b0566000' target=_blank style='color:#2F92EE;'>#DACTOS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5660, encryptionId=85b0566000, topicName=DACTOS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c838337, createdName=zhlpower, createdTime=Sun Apr 11 15:59:15 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779007, encodeId=b9141e790074b, content=<a href='/topic/show?id=e94f19102d' target=_blank style='color:#2F92EE;'>#Actos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1910, encryptionId=e94f19102d, topicName=Actos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Fri Jun 19 19:59:15 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862790, encodeId=61bd1862e90a6, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Nov 17 20:59:15 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718754, encodeId=172e1e1875463, content=<a href='/topic/show?id=5a6456425fc' target=_blank style='color:#2F92EE;'>#指炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56425, encryptionId=5a6456425fc, topicName=指炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f67632615255, createdName=xiongliangxl, createdTime=Fri Mar 12 00:59:15 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1266184, encodeId=c1d0126618453, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sat May 23 03:59:15 CST 2020, time=2020-05-23, status=1, ipAttribution=)]
    2020-11-17 gao_jian4217
  5. [GetPortalCommentsPageByObjectIdResponse(id=2013368, encodeId=f5f5201336895, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jul 09 22:59:15 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784071, encodeId=b8bb1e840719b, content=<a href='/topic/show?id=85b0566000' target=_blank style='color:#2F92EE;'>#DACTOS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5660, encryptionId=85b0566000, topicName=DACTOS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c838337, createdName=zhlpower, createdTime=Sun Apr 11 15:59:15 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779007, encodeId=b9141e790074b, content=<a href='/topic/show?id=e94f19102d' target=_blank style='color:#2F92EE;'>#Actos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1910, encryptionId=e94f19102d, topicName=Actos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Fri Jun 19 19:59:15 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862790, encodeId=61bd1862e90a6, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Nov 17 20:59:15 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718754, encodeId=172e1e1875463, content=<a href='/topic/show?id=5a6456425fc' target=_blank style='color:#2F92EE;'>#指炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56425, encryptionId=5a6456425fc, topicName=指炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f67632615255, createdName=xiongliangxl, createdTime=Fri Mar 12 00:59:15 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1266184, encodeId=c1d0126618453, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sat May 23 03:59:15 CST 2020, time=2020-05-23, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2013368, encodeId=f5f5201336895, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jul 09 22:59:15 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784071, encodeId=b8bb1e840719b, content=<a href='/topic/show?id=85b0566000' target=_blank style='color:#2F92EE;'>#DACTOS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5660, encryptionId=85b0566000, topicName=DACTOS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c838337, createdName=zhlpower, createdTime=Sun Apr 11 15:59:15 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779007, encodeId=b9141e790074b, content=<a href='/topic/show?id=e94f19102d' target=_blank style='color:#2F92EE;'>#Actos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1910, encryptionId=e94f19102d, topicName=Actos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Fri Jun 19 19:59:15 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862790, encodeId=61bd1862e90a6, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Nov 17 20:59:15 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718754, encodeId=172e1e1875463, content=<a href='/topic/show?id=5a6456425fc' target=_blank style='color:#2F92EE;'>#指炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56425, encryptionId=5a6456425fc, topicName=指炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f67632615255, createdName=xiongliangxl, createdTime=Fri Mar 12 00:59:15 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1266184, encodeId=c1d0126618453, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sat May 23 03:59:15 CST 2020, time=2020-05-23, status=1, ipAttribution=)]
    2020-05-23 lmm397

相关资讯

2020 香港共识声明:生物类改善病情的抗风湿药(DMARDs)治疗多关节型JIA、附着点炎相关关节炎和银屑病关节炎

幼年特发性关节炎(JIA)是儿童最常见的炎症性关节炎,自从引入生物制剂以来,其治疗方案已经扩大。依据最新的信息,来自中国香港的专家小组针对生物类改善病情的抗风湿药(DMARDs)治疗三种JIA亚型,即多关节型JIA(pcJIA)、附着点炎相关关节炎(ERA) 和银屑病关节炎(PsA)的相关内容提出了最新实践共识。

J Rheumatol:银屑病关节炎的经济负担评估及其功能状态与医疗费用的关系

PsA患者给医疗系统带来了巨大的经济负担。功能状态与费用高度相关,并且主要是由二级保健咨询的费用引起的。

Ann Rheum Dis:血清代谢组和脂质组差异确定了血清阴性类风湿性关节炎vs银屑病关节炎的潜在生物标志物

PsA和negRA具有不同的血清代谢组学和脂质组学特征,可以用作鉴别诊断的生物标志物。

J Rheumatol:银屑病关节炎中TNFi单药治疗与联合治疗的比较

与TNFi单药治疗相比,TNFi与csDMARD联合治疗并不影响疾病活动性或HAQ的改善,但可以改善TNFi的药物生存期。

2020 ILAR建议:资源贫乏地区银屑病关节炎的管理

2020年1月,国际风湿病协会联盟(ILAR)发布了资源贫乏地区银屑病关节炎的管理建议,银屑病关节炎是一种充满挑战的异质性疾病,此前一些发达国家发布的指南在资源贫乏的国家和地区可能不适合。本文主要针对资源贫乏地区银屑病关节炎的管理提出指导建议。

Arthritis Rheumatol:银屑病的结构性肌腱附着点病变与出现银屑病关节炎的风险升高相关

在银屑病患者中,存在结构性附着点病变和附着点皮质vBMD低与出现PsA的风险升高相关。